These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21057704)

  • 1. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
    Auwerda JJ; Yuana Y; Osanto S; de Maat MP; Sonneveld P; Bertina RM; Leebeek FW
    Thromb Haemost; 2011 Jan; 105(1):14-20. PubMed ID: 21057704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.
    van Doormaal F; Kleinjan A; Berckmans RJ; Mackman N; Manly D; Kamphuisen PW; Richel DJ; Büller HR; Sturk A; Nieuwland R
    Thromb Haemost; 2012 Jul; 108(1):160-5. PubMed ID: 22535219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.
    Campello E; Spiezia L; Radu CM; Bulato C; Castelli M; Gavasso S; Simioni P
    Thromb Res; 2011 May; 127(5):473-7. PubMed ID: 21256535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers.
    Bharthuar A; Khorana AA; Hutson A; Wang JG; Key NS; Mackman N; Iyer RV
    Thromb Res; 2013 Aug; 132(2):180-4. PubMed ID: 23856554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year.
    Thaler J; Koppensteiner R; Pabinger I; Ay C; Gremmel T
    Thromb Res; 2014 Nov; 134(5):1093-6. PubMed ID: 25262106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features.
    Thaler J; Ay C; Mackman N; Metz-Schimmerl S; Stift J; Kaider A; Müllauer L; Gnant M; Scheithauer W; Pabinger I
    Eur J Clin Invest; 2013 Mar; 43(3):277-85. PubMed ID: 23398637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
    van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
    Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.
    Sartori MT; Della Puppa A; Ballin A; Campello E; Radu CM; Saggiorato G; d'Avella D; Scienza R; Cella G; Simioni P
    Thromb Haemost; 2013 Aug; 110(2):378-85. PubMed ID: 23803674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
    Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
    Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections.
    Woei-A-Jin FJ; van der Starre WE; Tesselaar ME; Garcia Rodriguez P; van Nieuwkoop C; Bertina RM; van Dissel JT; Osanto S
    Thromb Res; 2014 May; 133(5):799-803. PubMed ID: 24657035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.